NO20070136L - Antitumor effekt potentiator, antitumor preparering og fremgangsmater for cancerterapi - Google Patents

Antitumor effekt potentiator, antitumor preparering og fremgangsmater for cancerterapi

Info

Publication number
NO20070136L
NO20070136L NO20070136A NO20070136A NO20070136L NO 20070136 L NO20070136 L NO 20070136L NO 20070136 A NO20070136 A NO 20070136A NO 20070136 A NO20070136 A NO 20070136A NO 20070136 L NO20070136 L NO 20070136L
Authority
NO
Norway
Prior art keywords
antitumor
potentiating
effect
amount effective
gimeracil
Prior art date
Application number
NO20070136A
Other languages
English (en)
Norwegian (no)
Inventor
Katsuhisa Koizumi
Junji Uchida
Teiji Takechi
Mamoru Nukatsuka
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of NO20070136L publication Critical patent/NO20070136L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20070136A 2004-06-09 2007-01-08 Antitumor effekt potentiator, antitumor preparering og fremgangsmater for cancerterapi NO20070136L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004171520 2004-06-09
PCT/JP2005/010182 WO2005120480A1 (ja) 2004-06-09 2005-06-02 抗腫瘍効果増強剤、抗腫瘍剤及び癌治療方法

Publications (1)

Publication Number Publication Date
NO20070136L true NO20070136L (no) 2007-02-09

Family

ID=35502806

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070136A NO20070136L (no) 2004-06-09 2007-01-08 Antitumor effekt potentiator, antitumor preparering og fremgangsmater for cancerterapi

Country Status (25)

Country Link
US (1) US20080306073A1 (es)
EP (1) EP1757283B1 (es)
JP (1) JP5578753B2 (es)
CN (2) CN1964707A (es)
AU (1) AU2005251588B2 (es)
BR (1) BRPI0511988A (es)
CA (1) CA2569739C (es)
CY (1) CY1113509T1 (es)
DK (1) DK1757283T3 (es)
EA (1) EA011573B1 (es)
ES (1) ES2393398T3 (es)
HR (1) HRP20121062T1 (es)
IL (1) IL179885A (es)
ME (1) ME01460B (es)
MX (1) MXPA06014477A (es)
MY (1) MY140563A (es)
NO (1) NO20070136L (es)
NZ (1) NZ551637A (es)
PL (1) PL1757283T3 (es)
PT (1) PT1757283E (es)
RS (1) RS52668B (es)
SI (1) SI1757283T1 (es)
TW (1) TWI324929B (es)
WO (1) WO2005120480A1 (es)
ZA (1) ZA200700134B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY151207A (en) * 2007-12-27 2014-04-30 Taiho Pharmaceutical Co Ltd Oral particulate antitumor preparation
TWI468188B (zh) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
WO2009139085A1 (ja) * 2008-05-12 2009-11-19 静岡県 抗腫瘍剤、キット及び癌治療方法
JP5553522B2 (ja) * 2009-03-31 2014-07-16 大鵬薬品工業株式会社 経口投与用医薬組成物
CN102309492A (zh) * 2010-07-02 2012-01-11 天津金耀集团有限公司 一种替加氟、吉美斯特和奥替拉西钾复方注射液
JPWO2013137433A1 (ja) * 2012-03-16 2015-08-03 大鵬薬品工業株式会社 ３剤を組み合わせた新規な抗腫瘍剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9508554A (pt) * 1994-08-08 1997-11-25 Debiopharm Sa Preparação farmaceuticamente estável de oxaliplatina
AU2001240001A1 (en) * 2000-03-08 2001-09-17 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
CA2457148A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations

Also Published As

Publication number Publication date
NZ551637A (en) 2010-05-28
EP1757283A1 (en) 2007-02-28
TW200603809A (en) 2006-02-01
CN1964707A (zh) 2007-05-16
RS52668B (en) 2013-06-28
EP1757283A4 (en) 2009-09-02
MXPA06014477A (es) 2007-03-21
AU2005251588A1 (en) 2005-12-22
CN103054871A (zh) 2013-04-24
IL179885A0 (en) 2007-05-15
BRPI0511988A (pt) 2008-01-22
DK1757283T3 (da) 2012-11-12
US20080306073A1 (en) 2008-12-11
TWI324929B (en) 2010-05-21
SI1757283T1 (sl) 2013-01-31
ME01460B (me) 2014-04-20
EP1757283B1 (en) 2012-10-17
WO2005120480A1 (ja) 2005-12-22
ZA200700134B (en) 2008-05-28
PL1757283T3 (pl) 2013-03-29
EA200602282A1 (ru) 2007-04-27
JP5578753B2 (ja) 2014-08-27
CA2569739A1 (en) 2005-12-22
IL179885A (en) 2011-08-31
AU2005251588B2 (en) 2009-01-08
CY1113509T1 (el) 2016-06-22
MY140563A (en) 2009-12-31
EA011573B1 (ru) 2009-04-28
HRP20121062T1 (hr) 2013-01-31
JPWO2005120480A1 (ja) 2008-04-03
PT1757283E (pt) 2012-12-07
CA2569739C (en) 2011-11-29
ES2393398T3 (es) 2012-12-21

Similar Documents

Publication Publication Date Title
NO20070136L (no) Antitumor effekt potentiator, antitumor preparering og fremgangsmater for cancerterapi
NO20061925L (no) Farmasoytiske preparater for forebyggelse av overdose eller misbruk
NO20072654L (no) Cancer behandling
NO20092150L (no) Fremgangsmater for behandling av hyperkolesterolemi
NO20055605L (no) Kombinasjonsprodukter for behandling av sykdommer som omfatter celleprofilerasjon, migrasjon eller apotose av myelomaceller, eller angiogenese
RU2011104570A (ru) КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
NO20070656L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
NO20073068L (no) Stereoisomere anrikete 3-aminokarbonylbisykloheptenpyrimidindiaminforindelser og deres anvendelse
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer
NO20060381L (no) Humane anti-NGF noytraliserende antistoffer som selektive HGF vei inhibitorer
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20070681L (no) 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft
CY1108395T1 (el) Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2009129531A3 (en) Bupivacaine formulation in a polyorthoester carrier
DE60108489D1 (de) Kombinationstherapien mit gefässschädigender aktivität
WO2006031706A3 (en) Betulinol derivatives as anti-hiv agents
WO2011128782A3 (en) Compositions and methods for treating type ii diabetes and related disorders
NO20052954L (no) Diterpenoidforbindelser, sammensetninger derav og deres anvendelse som anti-cancer eller anti-fungale midler
AU2002249103A1 (en) Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors
NO20072851L (no) Hoydose forlenget frigivelses formulering av gepiron
RU2010150760A (ru) Противоопухолевый агент, набор и способ лечения рака
NO20073942L (no) Farmasoytiske sammensetninger for behandling av sykdommer assosiert med NF-KB-aktivitet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application